All the conjugates targeted specifically HER2-expressing xenografts in mice, as the tumor uptake was reduced by pre-saturation of HER2 via pre-injection of large excess of non-labeled ZHER2∶342 (Figure 4). The gene discussed is ERBB2; the disease is neoplasm.